MEDCL Fundamental Analysis - MEDINCELL SA

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to MEDCL. MEDCL was compared to 52 industry peers in the Pharmaceuticals industry. The financial health of MEDCL is average, but there are quite some concerns on its profitability. MEDCL is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

MEDCL had negative earnings in the past year.

MEDCL had a negative operating cash flow in the past year.

MEDCL had negative earnings in each of the past 5 years.

In the past 5 years MEDCL reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of MEDCL (-26.49%) is worse than 76.92% of its industry peers.

		Industry Rank	Sector Rank
ROA	-26.49%
ROE	N/A
ROIC	N/A

ROA(3y)-65.62%

ROA(5y)-56.54%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MEDCL has a Gross Margin of 84.26%. This is amongst the best in the industry. MEDCL outperforms 92.31% of its industry peers.

MEDCL's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for MEDCL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	84.26%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.72%

GM growth 5Y7.65%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MEDCL has been increased compared to 1 year ago.

MEDCL has more shares outstanding than it did 5 years ago.

MEDCL has a better debt/assets ratio than last year.

2.2 Solvency

MEDCL has an Altman-Z score of 4.78. This indicates that MEDCL is financially healthy and has little risk of bankruptcy at the moment.

MEDCL's Altman-Z score of 4.78 is fine compared to the rest of the industry. MEDCL outperforms 71.15% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	4.78

ROIC/WACCN/A

WACC7.69%

2.3 Liquidity

MEDCL has a Current Ratio of 2.90. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.

MEDCL's Current ratio of 2.90 is amongst the best of the industry. MEDCL outperforms 84.62% of its industry peers.

A Quick Ratio of 2.90 indicates that MEDCL has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 2.90, MEDCL belongs to the top of the industry, outperforming 90.38% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.9
Quick Ratio	2.9

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MEDCL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.59%, which is quite impressive.

MEDCL shows a strong growth in Revenue. In the last year, the Revenue has grown by 169.98%.

The Revenue has been growing by 54.88% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)42.59%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%2%

Revenue 1Y (TTM)169.98%

Revenue growth 3Y83.86%

Revenue growth 5Y54.88%

Sales Q2Q%34.66%

3.2 Future

The Earnings Per Share is expected to grow by 50.22% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 40.22% on average over the next years. This is a very strong growth

EPS Next Y60.41%

EPS Next 2Y73.13%

EPS Next 3Y56.92%

EPS Next 5Y50.22%

Revenue Next Year13.44%

Revenue Next 2Y54.94%

Revenue Next 3Y67.72%

Revenue Next 5Y40.22%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MEDCL. In the last year negative earnings were reported.

A Price/Forward Earnings ratio of 33.06 indicates a quite expensive valuation of MEDCL.

MEDCL's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. MEDCL is more expensive than 67.31% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 23.13, MEDCL is valued a bit more expensive.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	33.06

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MEDCL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as MEDCL's earnings are expected to grow with 56.92% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y73.13%

EPS Next 3Y56.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MEDCL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDINCELL SA

EPA:MEDCL (12/31/2025, 7:00:00 PM)

25.2

+0.54 (+2.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)12-09 2025-12-09/amc

Earnings (Next)N/A N/A

Inst Owners30.76%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap834.88M

Revenue(TTM)28.80M

Net Income(TTM)-19.87M

Analysts84.71

Price Target35.99 (42.82%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.14%

PT rev (3m)52.32%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-88%

EPS NY rev (3m)-117.59%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-7.21%

Revenue NY rev (3m)-1.23%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	33.06
P/S	28.99
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.62

EYN/A

EPS(NY)0.76

Fwd EY3.02%

FCF(TTM)-0.6

FCFYN/A

OCF(TTM)-0.54

OCFYN/A

SpS0.87

BVpS-0.91

TBVpS-1

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.49%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	84.26%
FCFM	N/A

ROA(3y)-65.62%

ROA(5y)-56.54%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.72%

GM growth 5Y7.65%

F-Score5

Asset Turnover0.38

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	95.71%
Cap/Sales	6.98%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.9
Quick Ratio	2.9
Altman-Z	4.78

F-Score5

WACC7.69%

ROIC/WACCN/A

Cap/Depr(3y)71.48%

Cap/Depr(5y)81.15%

Cap/Sales(3y)10.03%

Cap/Sales(5y)17.67%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)42.59%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%2%

EPS Next Y60.41%

EPS Next 2Y73.13%

EPS Next 3Y56.92%

EPS Next 5Y50.22%

Revenue 1Y (TTM)169.98%

Revenue growth 3Y83.86%

Revenue growth 5Y54.88%

Sales Q2Q%34.66%

Revenue Next Year13.44%

Revenue Next 2Y54.94%

Revenue Next 3Y67.72%

Revenue Next 5Y40.22%

EBIT growth 1Y49.38%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year53.93%

EBIT Next 3Y96.47%

EBIT Next 5Y84.97%

FCF growth 1Y16.8%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y21.88%

OCF growth 3YN/A

OCF growth 5YN/A

MEDINCELL SA / MEDCL.PA FAQ

What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA.

Can you provide the valuation status for MEDINCELL SA?

ChartMill assigns a valuation rating of 2 / 10 to MEDINCELL SA (MEDCL.PA). This can be considered as Overvalued.

What is the profitability of MEDCL stock?

MEDINCELL SA (MEDCL.PA) has a profitability rating of 1 / 10.

What is the earnings growth outlook for MEDINCELL SA?

The Earnings per Share (EPS) of MEDINCELL SA (MEDCL.PA) is expected to grow by 60.41% in the next year.

MEDINCELL SA (MEDCL.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEDINCELL SA / MEDCL.PA FAQ

What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?

Can you provide the valuation status for MEDINCELL SA?

What is the profitability of MEDCL stock?

What is the earnings growth outlook for MEDINCELL SA?